Categories
Change Password!
Reset Password!
Elinzanetant markedly improves mood and work productivity in postmenopausal women with vasomotor symptoms, with most reporting meaningful changes in emotional wellbeing, focus, and daily performance.
New insights from Phase III trials highlight how a nonhormonal treatment helped women regain emotional stability and workplace efficiency amid menopausal hot flashes. Notably, postmenopausal women participating in two major Phase III clinical trials—OASIS 1 and 2—reported remarkable improvements in mood and work-related functioning after treatment with elinzanetant, according to findings from an exit interview study.
Vasomotor symptoms (VMS), like night sweats and hot flashes, disrupt daily life during menopause. Hence, this study sought to better comprehend the broader impact of VMS—specifically on emotional wellbeing and productivity—by collecting direct feedback from 40 women in the U.S. who had received elinzanetant either for 26 weeks or for 14 weeks following a placebo phase.
Conducted via 60-minute telephone interviews, the study employed a semi-structured format to explore participants’ experiences prior to and after treatment. Thematic analysis of transcripts revealed that prior to receiving elinzanetant, women frequently experienced negative emotional and occupational effects. Common mood-related issues encompassed reduced happiness (60%), embarrassment (50%), and mood swings (45%), while challenges at work centered around reduced concentration (77.5%) and productivity (67.5%).
Following treatment, most women reported meaningful improvements: at least 82.4% noted better mood, and 80% or more experienced enhanced focus and productivity. These benefits often translated into improved social wellbeing and overall quality of life. Furthermore, more than 72% of women described these changes as meaningful, and over 71% expressed high satisfaction with the outcomes. Researchers confirmed that the sample size was sufficient, as thematic saturation was attained.
The study’s qualitative data yield a deeper understanding of the day-to-day burdens connected with VMS and how effective treatment can lead to tangible emotional and functional gains. These interviews highlight the real-world value of elinzanetant beyond symptom relief. Moreover, the findings emphasize how addressing VMS can positively affect women’s mental health, productivity, and overall satisfaction during the menopausal transition. Thus, elinzanetant, as a nonhormonal option, could offer a promising alternative for those seeking relief from the multifaceted impact of menopause without the risks linked to hormonal therapies.
Patient
Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials
Claudia Haberland et al.
Comments (0)